Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04268030 · ClinicalTrials.gov registry record
High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 9
- Enrollment target
NCT04268030 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT04268030 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The aim is to study a specific group of PD patients, carriers of mutations in the glucocerebrosidase (GBA) gene, which is the most common genetic risk factor for PD and is a harbinger of aggressive cognitive and motor decline. Approximately 12-17% of PD patients undergoing DBS are GBA mutation carriers. GBA mutation carriers with PD have a specific phenotype characterized by more significant motor dysfunction and reduced short-term visual memory function compared with their non-GBA counterparts. Thus as GBA mutation carriers have a "signature" phenotype, the investigators hypothesize that these GBA mutation carriers have a unique "signature" of oscillatory activity that can be distinguished from non-mutation carriers during motor activation and during cognitive tasks. Identification of this "signature" will provide critical information that is required to: 1) understand the underlying neurophysiological mechanisms responsible for the aggressive disease course of GBA associated PD, and 2) further develop customized adaptive DBS systems.
Interventions
- OTHER collection of LFPs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2020-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04268030
The ClinicalTrials.gov registry entry for NCT04268030 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which collection of LFPs is the first listed.
NCT04268030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04268030 about?
NCT04268030 is a clinical study titled "High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement". The aim is to study a specific group of PD patients, carriers of mutations in the glucocerebrosidase (GBA) gene, which is the most common genetic risk factor for PD and is a harbinger of aggressive cognitive and motor decline. Approximately 12-17% of PD patients undergoing DBS are GBA mutation carri...
What is the current status of trial NCT04268030?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2020-02-11. Estimated completion is 2020-08-30.
What interventions are being tested in trial NCT04268030?
The interventions under investigation include: collection of LFPs (OTHER).
Who is sponsoring clinical trial NCT04268030?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.